| ||
| Oxigene Up 9% In Pre-Markets As S&P 500 Gains Ground Barron's (blog) The biotech reported encouraging data on a trial on a non-small cell lung cancer drug, Zybrestat. Also, Goldman Sachs (GS) could be a focus after the Wall Street Journal reported that it plans to push back the release of documents pertaining to bets it ... See all stories on this topic » | ||
| Cell>Point Presents Phase 2 Clinical Trial Results Comparing its 99mTc-EC-G ... Gamut News ... used to diagnose and stage patients with Non-Small Cell Lung Cancer (NSCLC) at the 2011 Society of Nuclear Medicine Annual Meeting on June 7, 2011. In the reported study, Cell>Point imaged 22 patients with biopsy-proven NSCLC with FDG PET/CT ... See all stories on this topic » | ||
| Wall Street Futures Drift Lower; Hot Stocks: AAPL, GOOG, GS, OXGN istockAnalyst.com (press release) OXiGENE Inc. (Nasdaq: OXGN) shares rose 12.15 percent to $4.80, after the company reported encouraging data in a Phase II trial of Zybrestat in non-small cell lung cancer. Asian markets closed mostly lower today. Singapore's Straits Times closed at ... See all stories on this topic » | ||
| Monday's biggest gaining and declining stocks MarketWatch By Kate Gibson, MarketWatch Oxigene Inc.'s /quotes/zigman/4149096/quotes/nls/oxgn OXGN +7.49% shares rose 7.5% after the biotech company on Saturday reported encouraging data on a potential treatment for non-small-cell lung cancer. ... See all stories on this topic » |
| ||
| Optimization of Small-Cell Lung Cancer Chemotherapy with Heparin ... Purpose: In first-line management for small-cell lung cancer (SCLC), the combination of a platinum salt and etoposide is recommended, with thoracic ... content.karger.com/ProdukteDB/produkte.asp?... |
This once a day Google Alert is brought to you by Google.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment